Adverse drug reactions associated with asthma medications in children: Systematic review of clinical trials

International Journal of Clinical Pharmacy

Volumn 36, Issue 2, 2014, Pages 243-252

  Aagaard, Lise ^a   Hansen, Ebba Holme ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adverse drug reactions; Asthma; Children; Pediatric indication; Pharmacovigilance

Indexed keywords

BAMBUTEROL; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL; FORMOTEROL FUMARATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MONTELUKAST; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE; ZAFIRLUKAST; ANTIASTHMATIC AGENT;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ASTHMA; BRONCHITIS; BRONCHOSPASM; CHICKENPOX; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG OVERDOSE; EAR DISEASE; EYE DISEASE; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; INJURY; NAUSEA; NOSE OBSTRUCTION; PARESTHESIA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; RHINORRHEA; SIDE EFFECT; SINUSITIS; SKIN ALLERGY; SORE THROAT; TONSILLITIS; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WHEEZING; ADOLESCENT; CHILD; FEMALE; INFANT; MALE; PRESCHOOL CHILD; PUBLISHING;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT; MALE; PUBLICATION BIAS;

EID: 84899952544     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-014-9924-y     Document Type: Review

References (28)

1. Thrane N, Sørensen HT. A one-year population-based study of drug prescriptions for Danish children. Acta Paediatr. 1999;88:1131-6. (Pubitemid 29489172)
2. Grover C, Armour C, Asperen PP, Moles R, Saini B. Medication use in children with asthma: not a child size problem. J Asthma. 2011;48:1085-103.
3. Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatr Allergy Immunol. 2011;22:469-76.
4. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf. 2010;33(4):327-39.
5. Star K, Noren N, Nordin K, Edwards RI. Suspected adverse drug reactions reported for children worldwide. An explanatory study using VigiBase. Drug Saf. 2011;34:415-28.
6. De Vries TW, de Langen-Wouterse JJ, van Puijenbroek E, Duiverman EJ, den Berg LTW. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343-6.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(6):e1000097. doi:10.1371/journal.pmed1000097.
8. Von Berg A, De Blic J, La Rosa M, Kaad PH, Moorat A. A comparison of regular salmeterol vs "as required" salbutamol therapy in asthmatic children. Respir Med. 1998;92:292-9. (Pubitemid 28116256)
9. Von Berg A, Papageorgiou F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbohaler in children. Int J Clin Pract. 2003;57:852-6. (Pubitemid 38088799)
10. Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: double-blind trial in asthmatic children using powder devices at a dosage of 400 mg/day. Eur Respir J. 1996;9:2263-72. (Pubitemid 26366652)
11. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-14-year-old children. JAMA. 1998;279:1181-6.
12. Pearlman DS, Lampl KL, Dowling PJ, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther. 2000;22:732-47. (Pubitemid 30451998)
13. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged C6 years. Clin Exp Allergy. 2000;31:77-87. (Pubitemid 32158764)
14. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2 to 5 years. Pediatr. 2001;108:e48.
15. Maspero JF, Duenas-Meza E, Volovitz B, Daza CP, Kosa L, Vrijens F, et al. Oral montelukast versus inhaled beclomethasone in 6-11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy. Curr Med Res Opin. 2001;17:96-104. (Pubitemid 32964000)
16. Bukstein DA, Bratton DL, Firriolo KM, Estojak J, Bird SR, Hustad CM, et al. Evaluation of parenteral preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma. 2003;40:475-85. (Pubitemid 37175481)
17. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone for control of asthma among 6-to 14-Year-old patients with mild asthma: the MOSAIC study. Pediatr. 2005;116:360-9. (Pubitemid 44161461)
18. Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability and exploratory efficacy of montelukast in 6-to-24-month-old patients with asthma. Curr Med Res Opin. 2005;21:971-9. (Pubitemid 40896245)
19. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulm. 2002;34:342-50. (Pubitemid 35192788)
20. Duggan EM, Sturley J, Fitzgerald AP, Perry IJ, Hourihane JO. The 2002-2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. Pediatr Allergy Immunol. 2012;23:464-71.
21. Beasley R, Holt S, Fabian D, Masoli M. Global burden of asthma. Global initiative for asthma (GINA). www.ginasthma.org/. Last accessed 4 July 2013.
22. National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.htm. Last accessed 4 July 2013.
23. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26. (Pubitemid 43265239)
24. Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs, and NSAIDs. BMC Clin Pharmacol. 2009;9:4.
25. Gøtzsche P, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industryinitiated clinical trials. JAMA. 2006;295:1645-6.
26. De Vries T, Van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomised controlled clinical trials. Arch Dis Child. 2010;95:1023-6.
27. Rogers L, Reibman J. Stepping down asthma treatment: how and when. Curr Opin Pulm Med. 2012;18:70-5.
28. Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;26:2457-65. (Pubitemid 38669189)